| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T499 |
0-197 |
Sentence |
denotes |
Against this background, the role of the attending physician is crucial, by favouring and not discouraging RCT participation (in favour of off-label administration) whenever the former is possible. |
| T500 |
198-472 |
Sentence |
denotes |
Otherwise, scientific data will still be produced, but most information will be burdened by only partially adjustable selection biases and confounding factors, with consequent risks of inconclusive results and low-level supporting evidence for the various treatment options. |
| T501 |
473-763 |
Sentence |
denotes |
If participation in RCT is maximized, high-level evidence will be available for guiding treatment, with lower-level evidence from off-label uses still remaining useful for hypothesis-generating purposes in order to better design further RCT (and not for directly guiding treatment choices). |
| T502 |
764-1233 |
Sentence |
denotes |
Notably, this is what, in our opinion, happened with LPV/RTV: (a) preclinical data supported activity against coronaviruses; (b) patients were enrolled onto RCT whenever possible, and otherwise they were offered off-label administration when not spontaneously improving; (c) because many patients were rapidly enrolled onto the first RCT, evidence rapidly become available that in our opinion discouraged a universal off-label provision of LPV/RTV in COVID-19 patients. |
